Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products

The price of enhanced half-life factor IX.

Chimeric antibodies with extended half-life in ferrets

BACKGROUND Ferrets have long been used as a disease model for the study of influenza vaccines, but a more recent use has been for the study of human monoclonal antibodies directed against influenza viruses. Published data suggest that human antibodies are cleared unusually quickly from the ferret and that immune responses may be partially responsible. This immunogenicity increases variability w...

The half-life of 87Rb.

The half-life of 87Rb was measured by a liquid scintillation method according to the efficiency tracing method. The measuring sample of rubidium chloride was dissolved in a scintillation cocktail of Insta-gel, and the rubidium was determined by gravimetry as tetraphenylborate. The result was (5.56 +/- 0.025) x 10(10) years.

Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.

The prophylactic administration of factor IX (FIX) is considered the most effective treatment for haemophilia B. The inter-individual variability and complexity of the pharmacokinetics (PK) of FIX, and the rarity of the disease have hampered identification of an optimal treatment regimens. The recent introduction of extended half-life recombinant FIX molecules (EHL-rFIX), has prompted a thoroug...

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates

The development of a new generation of coagulation factors with improved pharmacokinetic profile will change the paradigm of treatment of persons with hemophilia (PWH). The standard treatment in PWH is represented by regular long-term prophylaxis that, given intravenously twice or thrice weekly, is associated with a not-negligible burden on patients' quality of life. The availability of drugs w...